Background: We launched an in-house clinical sequencing system called "CLHURC" in April 2016. Since then, we have conducted comprehensive genetic testing for several cancer-related genes for patients with all types of cancers, including pancreatic cancer. We aimed to analyze the clinical utility of this system as a medical service. Methods: Genomic DNA was extracted from both tumor tissue and normal blood serum obtained from the patients. We then performed a targeted amplicon exome sequencing for 160 cancer-related genes using a next-generation sequencing platform. Gene alterations were identified using our in-house automated gene analysis system. The significance of the gene alterations and recommended treatments based on the genomic information were discussed at the team-conference consisting of medical oncologists, pathologists, clinical laboratory technologists, bioinformaticians and clinical geneticists. We conclusively prepared a report for individual patients with their genomic information, which includes the actionable and druggable gene alterations, and variants of uncertain significance. Results: We performed clinical sequencing for 81 patients with cancer between April and December 2016. Within this cohort, 14 patients had pancreatic cancer. Reliable sequencing results were obtained for 13 of those patients and actionable gene alterations were detected in all the patients (13/13, 100%). However, potentially druggable gene alterations were detected only for four patients in the genes ARID1A, BRCA2, FGFR, and TSC1) (4/13, 31%). Interestingly, incidental germline variants were detected in three genes: BRCA2, CDK12, and TSC1) (3/13, 23%). The median period of the examination was 16 days (9-30 days). Conclusions: Our clinical sequencing system provided valuable genomic information to almost one-third of our patients with pancreatic cancer and allowed for a selection of anticancer drug options within about three weeks. Gastroenterology, Gifu Municipal Hospital FOLFIRINOX (FX) was reported as effective treatment for unresectable advanced pancreatic cancer (UAPC). However, because of combination chemotherapy, FX is associated with a higher incidence of adverse events (AEs). In a phase 2 study in Japan showed higher incidence of grade(G) 3 or 4 AEs including febrile neutropenia (FN: 22.2%). Modified FX (mFX) by omitting the bolus 5-FU and reducing irinotecan may decrease AEs and can be more effective than FX by improving treatment compliance. Aims: To assess the safety and efficacy of first-line mFX for UAPC.
Gastroenterology, Gifu Municipal Hospital FOLFIRINOX (FX) was reported as effective treatment for unresectable advanced pancreatic cancer (UAPC). However, because of combination chemotherapy, FX is associated with a higher incidence of adverse events (AEs). In a phase 2 study in Japan showed higher incidence of grade(G) 3 or 4 AEs including febrile neutropenia (FN: 22.2%). Modified FX (mFX) by omitting the bolus 5-FU and reducing irinotecan may decrease AEs and can be more effective than FX by improving treatment compliance. Aims: To assess the safety and efficacy of first-line mFX for UAPC.
Patients and methods: his study was multicenter prospective phase 2 study. Inclusion criteria were 1) age of 20-75 y.o., 2) ECOG PS of 0 or 1 and 3) pathologically confirmed pancreatic adeno-or adenosquamous-carcinoma between 10/2014 and 3/2016. Exclusion criteria were followings: 1) h/o chemotherapy or 2) homozygous UGT1A1*28/*6 or heterozygous UGT1A1*6 and *28. Treatment with mFX (i.v. infusion of 85mg/m2 oxaliplatin, 150mg/m2 irinotecan, and 200mg/m2 l-leucovorin, followed by a 46-h continuous infusion of 2400mg/m2 5-FU) was given every 2 weeks. The primary endpoint was response rate (RR). The secondary endpoints were overall survival (OS), progression-free survival (PFS) and safety. Results: 31 patients (18 men, median age of 64 y.o.) were enrolled. PS was 0 in 25 and 1 in 6. The tumor was located in the head in 15 and the body/tail in 16. Biliary stent was placed in 8. Metastasis was recognized in 21. The median number of treatment cycles was 13. The response rate was 38.7%. The median follow-up time was 18.4 months. The median OS was 15.2 months, and the median PFS was 7.1 months. G3 or 4 AEs included neutropenia (84%), FN (16.1%), peripheral sensory neuropathy (9.7%), thrombocytopenia (6.5%), diarrhea (6.5%), anorexia (6.5%) and vomiting (3.2%). Conclusion: Compared to full-dose FX, mFX may reduce G3 or 4 AEs with comparable efficacy. Thus, mFX may improve the quality of life in patients with UAPC. Introduction: In diffuse large B-cell lymphoma (DLBCL), reduced anticancer agent doses and prolonged inter-treatment intervals result in lower treatment intensity and a decreased cure rate. Since febrile neutropenia (FN) is the most significant adverse event of decreasing the treatment intensity, the FN Study Group in the Japanese Association of Supportive Care in Cancer (JASCC) designed a questionnaire on FN during R-CHOP therapy and conducted a survey in cooperation with the Japanese Society of Medical Oncology (JSMO). Methods: The survey was conducted from July 25 to August 22, 2016. The subjects were regular members of the JSMO. Responses to 65 questions were requested using Survey MonkeyV R on the Internet, and the results were aggregated. Results: Responses were received from 336 (4%) of the 8,158 JSMO members. The percentage of those facilities with an emergency department to respond to FN 24 hours a day was 72%. In outpatient FN treatment, 39.5% responded that patients are examined in the respondent's own department within regular hours and handled by the emergency department in their facility outside of regular hours. Patients are treated in 25.5% of the respondents' own departments 24 hours a day, and are prescribed oral antibiotics in advance and instructed to take them if they develop a fever. If there is no improvement or exacerbation, the patient is examined in 14.4% of the respondents' facilities. The most commonly used drugs in outpatient FN treatment are oral new quinolones (66.8%). With non-elderly patients (<65 years old), 16.4% said that they reduced the dose based on specific criteria from the first treatment, while 39.8% said that they did not reduce the dose if inpatient treatment for a full cycle was possible. 
